Sanara MedTech Inc(SMTI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:30 PM ET (Korea 9/12 08:30)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -3.71 | Insider Own | 47.06% | Shs Outstand | 9.2M | Perf Week | 0.58% |
| Market Cap | 0.32B | Forward P/E | 59.69 | EPS next Y | 207.89% | Insider Trans | - | Shs Float | 4.9M | Perf Month | 1.72% |
| Enterprise Value | 0.35B | PEG | - | EPS next Q | 0.06 | Inst Own | 18.1% | Short Float | 5.77% | Perf Quarter | 62.42% |
| Income | -0.03B | P/S | 2.92 | EPS this Y | 480% | Inst Trans | -9.76% | Short Ratio | 1.13 | Perf Half Y | 82.92% |
| Sales | 0.11B | P/B | 40.41 | EPS next 5Y | - | ROA | -0.34% | Short Interest | 0.28M | Perf YTD | 49.55% |
| Book/sh | 0.86 | P/C | 20.81 | EPS past 3/5Y | -63.11% -41.8% | ROE | -1.31% | 52W High | -2.18% ($35.70) | Perf Year | -1.02% |
| Cash/sh | 1.68 | P/FCF | 71.3 | Sales past 3/5Y | 31.03% 45.92% | ROIC | -57.08% | 52W Low | 117.62% ($16.05) | Perf 3Y | -0.51% |
| Dividend Est. | - | EV/EBITDA | 25.5 | EPS Y/Y TTM | -219.19% | Gross Margin | 90.77% | Volatility(W/M) | 0.69% 0.67% | Perf 5Y | 2.89% |
| Dividend TTM | - | EV/Sales | 3.22 | Sales Y/Y TTM | 12.93% | Oper. Margin | 10.38% | ATR (14) | 0.41 | Perf 10Y | 676% |
| Dividend Ex-Date | - | Quick Ratio | 2.3 | EPS Q/Q | 77.64% | Profit Margin | -29.15% | RSI (14) | 75.28 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.58 | Sales Q/Q | 8.93% | SMA20 | 0.91% ($34.61) | Beta | 1.18 | Target Price | $35 |
| Payout | - | Debt/Eq | 6.11 | Earnings | 2026/8/11 | SMA50 | 12.85% ($30.94) | Rel Volume | 0.76 | Prev Close | $35.03 |
| Employees | 108 | LT Debt/Eq | 6.06 | EPS/Sales Surpr. | -100% -2.81% | SMA200 | 48.35% ($23.54) | Avg Volume(3M) | 0.25M | Price | $34.92 |
| IPO | 1994/4/7 | Option/Short | No/Yes | Trades | 1554 | Volume | 189,272 | Change | -0.31% |
Company
SMTI is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🩹 This is a US medical device company that supplies collagen-based advanced wound care treatments and surgical adjuncts. It has a portfolio of high-margin surgical products, including CellerateRX Surgical and BIASURGE, and is targeting the surgical adjunct market through an extensive network of healthcare facilities and distribution partners.
Over the past 1 year, on the higher side
2% below its 1-year high.
SMTI has weak earning power
10.38% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +480.0% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Long-term returns are close to the market
Would have changed by -0.5% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 18.1%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
IWC 0.00%
FLQS 0.00%
ITWO 0.00%
GSSC 0.00%
HDG 0.00%It ranks #4 in the industry
Based on market cap of $321M.
SMTI $321M PER -
ISRG $131B PER 42.4
BDX $48B PER 53.6
MDLN $43B PER 38.1
FAQ
What kind of company is SMTI?
SMTI belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is the market cap of SMTI?
The market cap of SMTI is approximately $321M, ranking 3,655 within its sector.
What is the 52-week high and low for SMTI?
SMTI has recorded a 52-week high of $35.70 and a low of $16.05.
